Transdermal Patch: Clinical Trials

14 trials of Transdermal Patch, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed. 14 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Completed 14
Phase 34Completed 4
Phase 11Completed 1

Follow Transdermal Patch: new trials by email Literature Review of Transdermal Patch trials Research Report on Transdermal Patch

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1 of 3)
Combination Nicotine Replacement Therapy (patch and lozenge) - Remote vs. In-Person, Remote Visits
Phase 2 / Phase 3CompletedState University of New York at Buffalo2002025-03-102026-11-05
Transgender Estradiol Affirming Therapy
Transdermal patch, Pro-thrombotic markers, Metabolic markers - Transgenderism
Phase 2CompletedWashington University School of Medicine392021-08-022024-11-26
Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
levonorgestrel - Healthy
Phase 1 / Phase 2CompletedAgile Therapeutics362012-07-012018-01-23
Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
Oleogel-S10, Mepilex® soft silicone faced polyurethane foam dressing - Inherited Epidermolysis Bullosa
Phase 2CompletedBirken AG102010-11-012018-01-23
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
Skin biopsy, Lidocaine 5% patches - Diabetic Peripheral Neuropathy
Phase 2 / Phase 3CompletedAlbany Medical College512009-10-012020-06-11
Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome
Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch - Carpal Tunnel Syndrome
Phase 2CompletedZARS Pharma Inc.242009-09-012012-03-16
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2% - Allergic Conjunctivitis
Phase 2CompletedSenju USA, Inc.1222009-02-012023-08-04
Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration
Patch, Placebo patch - Allergic Rhinoconjunctivitis
Phase 2CompletedUniversity of Zurich972008-10-012011-02-01
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Fentanyl 1-day transdermal patch (Titration Phase), Fentanyl 1-day transdermal patch (Double Blind Phase), Fentanyl 3-day transdermal patch (Double Blind Phase) - Pain, Cancer
Phase 2 / Phase 3CompletedJanssen Pharmaceutical K.K.1562007-12-012013-06-13
Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee
Lidoderm (Lidocaine 5% Patch), Placebo Patch - Osteoarthritis of the Knee
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company1692007-03-012017-10-05
Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia
Transdermal/Patch (Bupivacaine TTS [Eladur™]) - Postherpetic Neuralgia, Pain
Phase 2CompletedDurect602006-09-012009-09-11
Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee
Lidoderm, Placebo patch - Osteoarthritis, Knee
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company2242004-08-012010-02-10
A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain
Lidoderm®, Placebo Topical Patch - Chronic Low Back Pain
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company2152004-08-012013-12-06
Testosterone Replacement Therapy in Chronic Spinal Cord Injury
Testosterone Transdermal System (Androderm 5 mg patch) - Spinal Cord Injury, Hypogonadism
Phase 2 / Phase 3CompletedVA Office of Research and Development312003-08-012017-11-01

Conditions studied

Pain (3)  ·  Osteoarthritis, Knee (2)  ·  Carpal Tunnel Syndrome (1)  ·  Conjunctivitis, Allergic (1)  ·  Epidermolysis Bullosa (1)  ·  Herpes Zoster (1)  ·  Hypogonadism (1)  ·  Neoplasms (1)  ·  Neuralgia (1)  ·  Neuralgia, Postherpetic (1)  ·  Osteoarthritis (1)  ·  Spinal Cord Injuries (1)  ·  Transsexualism (1)

Sponsors

Endo USA Inc., a Keenova Therapeutics Company (3)  ·  Agile Therapeutics (1)  ·  Albany Medical College (1)  ·  Birken AG (1)  ·  Durect (1)  ·  Janssen Pharmaceutical K.K. (1)  ·  Senju USA, Inc. (1)  ·  State University of New York at Buffalo (1)  ·  University of Zurich (1)  ·  VA Office of Research and Development (1)  ·  Washington University School of Medicine (1)  ·  ZARS Pharma Inc. (1)

Countries

United States (10)  ·  Germany (1)  ·  Japan (1)  ·  Switzerland (1)

Top investigators

Agnes Schwieger-Briel, MD (1)  ·  Elizabeth Garner, MD, PHD (1)  ·  Ernest A. Kopecky, PhD, MBA (1)  ·  Gail Torkildsen, MD (1)  ·  Ginger Nicol, MD (1)  ·  Srinivas Nalamachu, MD (1)  ·  William Bauman, MD (1)

Results publications

PMID 21252493, PMID 21717386, PMID 23343764, PMID 24968251, PMID 38133914, PMID 42947186

NIH funding

UH3TR004797 (1)